

**IN THE CLAIMS:**


New claims 22-24 have been added. Claim 21 has been canceled. Claims 1 and 6 have been amended. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

**Listing of the Claims:**

1. (Currently amended) ~~An antiparasitic~~ formulation, wherein:

the formulation comprises one or more spinosyns in combination with one or more compounds of formula (I) and/or salts thereof;

formula (I) corresponds in structure to:



Ar is 2,6-dichloro-4-trifluoromethylphenyl or 2-nitro-4-trifluoromethylphenyl;

A is S(O)<sub>m</sub>, CH=CH, O, or NH;

as to W and Z:

W is N, and Z is CR<sup>5</sup>; or

W is CR<sup>1</sup>, and Z is N or CR<sup>5</sup>;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, halogen, or R<sup>20</sup>S(O)<sub>q</sub>;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, aryl, cyano, halogen, nitro, YR<sup>20</sup>, S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, CHO, NR<sup>8</sup>R<sup>9</sup>, or CYNR<sup>8</sup>R<sup>9</sup>;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, acyl, or optionally substituted alkoxy carbonyl;

R<sup>5</sup> is hydrogen, alkyl, optionally substituted amino, or halogen;

$R^8$  and  $R^9$  are independently hydrogen, optionally substituted alkyl, acyl, or aryl;

$R^{20}$  is optionally substituted alkyl;

Y is O or S;

m is zero, 1, or 2;

p is zero or 1;

n is zero, 1, or 2;

q is zero, 1, or 2;

any alkyl, alkoxy, or alkylthio comprises 1 to 4 carbon atoms;

any alkenyl or alkynyl comprises 2 to 5 carbon atoms;

the alkyl, alkoxy, alkylthio, alkenyl, or alkynyl portion of any substituted alkyl, alkoxy, alkylthio, alkenyl, or alkynyl is substituted by one or more substituents independently selected from the group consisting of halogen,  $YR^{20}$ , dihalocyclopropyl, cyano, nitro, optionally substituted amino, acyloxy, and aryl;

any aryl is phenyl optionally substituted by halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, haloalkylsulphonyl, cyano, or nitro;

any acyl is alkanoyl comprising 1 to 4 carbon atoms, alkylsulphonyl, or haloalkylsulphonyl;

any optionally substituted amino is  $NR^8R^9$ ; and

$R^4$  is not alkyl when:

W is  $CR^1$ ,

Z is  $CR^5$ , and

n and p are both zero, wherein, at a spinosyn dosage of less than or equal to 30 mg/kg, the formulation is capable of achieving an efficacy of 90% in controlling flea and tick infestations in an animal 7 days after administration of the formulation as may be determined by a parasite assessment test.

2. (Previously presented) The formulation according to claim 1, wherein the compound of formula (I) is 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl)-3-methyl-1-H pyrazole or a salt thereof.

3. (Previously presented) The formulation according to claim 1, wherein the formulation comprises a mixture of two or more spinosyns.

4. (Previously presented) The formulation according to claim 3, wherein the mixture is spinosad.

5. (Previously presented) The formulation according to claim 1, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the one or more spinosyns is from 1:10 to 10:1.

6. (Currently amended) A method of controlling an ectoparasite infestation in an animal, wherein persistent efficacy against flea and ticks is achieved for 7 days after treatment, wherein the method comprises comprising:

simultaneously or sequentially administering to the animal:

~~one or more spinosyns, and~~

~~one or more compounds of formula (I) recited in claim 1~~ the formulation (and/or salts thereof) of claim 1, wherein the one or more spinosyns are administered to the animal at a dosage of less than or equal to 30 mg/kg so as to achieve persistent efficacy of 90% in killing fleas and ticks for 7 days after the treatment.

7. (Previously presented) The method according to claim 6, wherein the method comprises administering:

spinosad, and

5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl)-3-methyl-1-H pyrazole or a salt thereof.

8. (Previously presented) The method according to claim 6, wherein the one or more spinosyns and one or more compounds of formula (I) (and/or salts thereof) are administered simultaneously.

9. (Previously presented) The method according to claim 8, wherein the one or more spinosyns and one or more compounds of formula (I) (and/or salts thereof) are in a single preparation.

10. (Previously presented) The method according to claim 6, wherein the ectoparasites are ticks.

11. (Previously presented) The method according to claim 6, wherein the ectoparasites are fleas.

12. (Previously presented) The formulation according to claim 2, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl)-3-methyl-1-H pyrazole (or salt thereof) to the one or more spinosyns is from 1:10 to 10:1.

13. (Previously presented) The formulation according to claim 2, wherein the formulation comprises a mixture of two or more spinosyns.

14. (Previously presented) The formulation according to claim 3, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the two or more spinosyns is from 1:10 to 10:1.

15. (Previously presented) The formulation according to claim 4, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the spinosad is from 1:10 to 10:1.

16. (Previously presented) The formulation according to claim 13, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the two or more spinosyns is from 1:10 to 10:1.

17. (Previously presented) The formulation according to claim 13, wherein the mixture is spinosad.

18. (Previously presented) The formulation according to claim 17, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the spinosad is from 1:10 to 10:1.

19. (Previously presented) The method according to claim 7, wherein the spinosad and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) are administered simultaneously.

20. (Previously presented) The method according to claim 19, wherein spinosad and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) are in a single preparation.

21. (Canceled).

22. (New) The method according to claim 6 further comprising:  
on a weekly basis, subsequently administering to the animal a reduced dosage of the formulation of claim 1 so as to maintain 90% efficacy against ticks for up to 7 days after the subsequent administration.

23. (New) The method according to claim 22, wherein the reduced dosage comprises less than or equal to 15 mg/kg of one or more spinosyns.

24. (New) The method according to claim 22, wherein the animal has been reinfested.